
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
G1 THERAPEUTICS DL-,0001 G1H US3621LQ1099 BAW/UFN
© 2024 Xetra Newsboard
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
18.09.24 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 18.09.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 18.09.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 18.09.2024ISIN NameCA05461V2012 AXMIN... ► Artikel lesen | |
18.09.24 | Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer | - Transaction Will Maximize the Access and Uptake of COSELA® (trilaciclib), the First and Only Proactive Multilineage Myeloprotection Agent - - G1 Stockholders to Receive U.S. $7.15 Per Share in Cash... ► Artikel lesen | |
18.09.24 | XFRA G1H: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILG1 THERAPEUTICS... ► Artikel lesen | |
05.09.24 | Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period | HOLBAEK, Denmark and RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharmacosmos A/S, a leader in the development of innovative treatments for patients suffering from iron deficiency... ► Artikel lesen | |
08.08.24 | G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights | - Entered into Definitive Merger Agreement to be Acquired by Pharmacosmos; Transaction Expected to Close in Late Third Quarter 2024 - - Achieved $15.8 Million in Net Revenue from Sales of COSELA®... ► Artikel lesen |